Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC

Amivantamab, an antibody against MET and EGFR, plus lazertinib, an EGFR tyrosine kinase inhibitor, induced a response in 86% of previously untreated patients and led to a median progression-free survival of nearly 2 years.

Saved in:

Bibliographic Details
Published in:	The New England journal of medicine Vol. 391; no. 16; pp. 1486 - 1498
Main Authors:	Cho, Byoung C., Lu, Shun, Felip, Enriqueta, Spira, Alexander I., Girard, Nicolas, Lee, Jong-Seok, Lee, Se-Hoon, Ostapenko, Yurii, Danchaivijitr, Pongwut, Liu, Baogang, Alip, Adlinda, Korbenfeld, Ernesto, Mourão Dias, Josiane, Besse, Benjamin, Lee, Ki-Hyeong, Xiong, Hailin, How, Soon-Hin, Cheng, Ying, Chang, Gee-Chen, Yoshioka, Hiroshige, Yang, James C.-H., Thomas, Michael, Nguyen, Danny, Ou, Sai-Hong I., Mukhedkar, Sanjay, Prabhash, Kumar, D’Arcangelo, Manolo, Alatorre-Alexander, Jorge, Vázquez Limón, Juan C., Alves, Sara, Stroyakovskiy, Daniil, Peregudova, Marina, Şendur, Mehmet A.N., Yazici, Ozan, Califano, Raffaele, Gutiérrez Calderón, Vanesa, de Marinis, Filippo, Passaro, Antonio, Kim, Sang-We, Gadgeel, Shirish M., Xie, John, Sun, Tao, Martinez, Melissa, Ennis, Mariah, Fennema, Elizabeth, Daksh, Mahesh, Millington, Dawn, Leconte, Isabelle, Iwasawa, Ryota, Lorenzini, Patricia, Baig, Mahadi, Shah, Sujay, Bauml, Joshua M., Shreeve, S. Martin, Sethi, Seema, Knoblauch, Roland E., Hayashi, Hidetoshi
Format:	Journal Article
Language:	English
Published:	United States Massachusetts Medical Society 24-10-2024
Subjects:	Antitumor activity Chemotherapy Confidence intervals Critical Care Critical Care General Epidermal growth factor receptors Hematology Hypotheses Hypothesis testing Kinases Lung Cancer Magnetic resonance imaging Metastases Metastasis Monoclonal antibodies Mutation Non-small cell lung carcinoma Oncology Pulmonary Small cell lung carcinoma Statistical analysis Survival analysis Targeted cancer therapy Treatments in Oncology
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Amivantamab, an antibody against MET and EGFR, plus lazertinib, an EGFR tyrosine kinase inhibitor, induced a response in 86% of previously untreated patients and led to a median progression-free survival of nearly 2 years.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3
ISSN:	0028-4793 1533-4406 1533-4406
DOI:	10.1056/NEJMoa2403614